BRPI0410419A - tratamento para a ansiedade com ziprasidona - Google Patents
tratamento para a ansiedade com ziprasidonaInfo
- Publication number
- BRPI0410419A BRPI0410419A BRPI0410419-6A BRPI0410419A BRPI0410419A BR PI0410419 A BRPI0410419 A BR PI0410419A BR PI0410419 A BRPI0410419 A BR PI0410419A BR PI0410419 A BRPI0410419 A BR PI0410419A
- Authority
- BR
- Brazil
- Prior art keywords
- anxiety
- formula
- mammal
- ziprasidone
- treatment
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 8
- 230000036506 anxiety Effects 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 title abstract 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000607 ziprasidone Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- -1 piperazinyl heterocyclic compounds Chemical class 0.000 abstract 2
- 241000239290 Araneae Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000001716 specific phobia Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000009182 swimming Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
"TRATAMENTOS PARA A ANSIEDADE COM ZIPRASIDONA". A presente invenção, em um aspecto, refere-se a um método de utilizar os compostos heterocíclicos de piperazinila de fórmula I, tal como abaixo definidos, para o tratamento em um mamífero, incluindo um ser humano, da ansiedade situacional, como por exemplo, a ansiedade sentida antes de intervenções médicas (por exemplo, cirurgia), de falar em público, bem como a ansiedade associada ao ato de nadar ou à água, a ansiedade associada às viagens (por exemplo, viajar de avião), ou a ansiedade associada a fobias específicas (cobras, aranhas, ratos, ver sangue), compreendendo a administração de uma quantidade terapeuticamente eficaz de um composto de fórmula I ao mamífero. Em um outro aspecto, a presente invenção tem por objeto um método de utilização dos compostos heterocíclicos de piperazinila da fórmula I, tal como definidos abaixo, para tratar em um mamífero, incluindo um ser humano, a ansiedade resistente ao tratamento, cujo método compreende a administração de uma quantidade farmaceuticamente eficaz de um composto de fórmula I ao referido mamífero. Os compostos de fórmula I são definidos da seguinte forma: ou um seu sal de adição de ácido farmaceuticamente aceitável, em que Ar, n, X, e Y são tal como definido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47138303P | 2003-05-16 | 2003-05-16 | |
| PCT/IB2004/001561 WO2004100955A1 (en) | 2003-05-16 | 2004-05-05 | Anxiety treatments with ziprasidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0410419A true BRPI0410419A (pt) | 2006-05-30 |
Family
ID=33452444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0410419-6A BRPI0410419A (pt) | 2003-05-16 | 2004-05-05 | tratamento para a ansiedade com ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050004138A1 (pt) |
| EP (1) | EP1633361A1 (pt) |
| JP (1) | JP2007522095A (pt) |
| AR (1) | AR044336A1 (pt) |
| BR (1) | BRPI0410419A (pt) |
| CA (1) | CA2525868A1 (pt) |
| MX (1) | MXPA05012392A (pt) |
| TW (1) | TW200427451A (pt) |
| WO (1) | WO2004100955A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323451T7 (es) | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| AR056968A1 (es) * | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| JP2009524637A (ja) * | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| WO2008060789A2 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| US20110294842A9 (en) * | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| JP5367824B2 (ja) * | 2008-09-22 | 2013-12-11 | エフ．ホフマン−ラ ロシュ アーゲー | ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬 |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| JO3032B1 (ar) * | 2008-10-17 | 2016-09-05 | Xenon Pharmaceuticals Inc | مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية. |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| KR20120099429A (ko) | 2009-10-14 | 2012-09-10 | 제논 파마슈티칼스 인크. | 스피로-옥스인돌 화합물의 합성 방법 |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| WO2011106729A2 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| DK0904273T3 (da) * | 1996-05-07 | 2003-07-07 | Pfizer | Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| CA2324813A1 (en) * | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| AU783516B2 (en) * | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
| CN1703198A (zh) * | 2002-10-25 | 2005-11-30 | 辉瑞产品公司 | 呈混悬剂形式的芳基杂环活性物质的贮库制剂 |
-
2004
- 2004-05-05 CA CA002525868A patent/CA2525868A1/en not_active Abandoned
- 2004-05-05 MX MXPA05012392A patent/MXPA05012392A/es unknown
- 2004-05-05 EP EP04731229A patent/EP1633361A1/en not_active Withdrawn
- 2004-05-05 WO PCT/IB2004/001561 patent/WO2004100955A1/en not_active Ceased
- 2004-05-05 JP JP2006530651A patent/JP2007522095A/ja active Pending
- 2004-05-05 BR BRPI0410419-6A patent/BRPI0410419A/pt not_active IP Right Cessation
- 2004-05-14 AR ARP040101651A patent/AR044336A1/es unknown
- 2004-05-14 US US10/845,824 patent/US20050004138A1/en not_active Abandoned
- 2004-05-14 TW TW093113658A patent/TW200427451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004100955A1 (en) | 2004-11-25 |
| AR044336A1 (es) | 2005-09-07 |
| CA2525868A1 (en) | 2004-11-25 |
| MXPA05012392A (es) | 2006-02-02 |
| EP1633361A1 (en) | 2006-03-15 |
| TW200427451A (en) | 2004-12-16 |
| US20050004138A1 (en) | 2005-01-06 |
| JP2007522095A (ja) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0410419A (pt) | tratamento para a ansiedade com ziprasidona | |
| BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
| BRPI0413930A (pt) | composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BRPI0712322A2 (pt) | compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos | |
| DE60036456D1 (de) | Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid | |
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| DE60213404D1 (de) | Verwendung von sulodexid zur behandlung von reizdarm | |
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| BRPI0607460A2 (pt) | braquiterapia periférica de órgãos protrusos moldáveis | |
| EP1596868A4 (en) | METHOD FOR TREATING HEAVY HEART FAILURE AND MEDICAMENT THEREFOR | |
| ATE422357T1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| JP2021502392A5 (pt) | ||
| EP2545929A4 (en) | Means for the alleviation or cure of chronic prostatitis, interstitial cystitis or bladder-weaning disorders | |
| ATE553760T1 (de) | Verwendung von alverin zur behandlung von hauterkrankungen | |
| NO20054180D0 (no) | Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| BR0014667A (pt) | Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012. |